News Pathos AI's big $365m Series D, and other bio financings Our round-up of recent biotech financings includes rounds for Pathos AI, Stylus Medicine, Haya Therapeutics, Therini Bio and Tiltbio.
News Lilly to hunt non-coding DNA for obesity drugs in $1bn deal Swiss start-up Haya Therapeutics has formed a partnership with Eli Lilly – worth up to $1 billion – to look for new therapies for obesity in non-coding DNA.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
